强直性脊柱炎疾病活动相关细胞因子分析

doi:10.3969/j.issn.1006-6233.2019.11.045

摘要
图/表
参考文献
相关文章 (12)

[1] Li, DH,He, CR,Liu, FP, et al.Annexin A2, up-regulated by IL-6, promotes the ossification of ligament fibroblasts from ankylosing spondylitis patients[J].Biomedicine & Pharmacotherapy,2016,84(9):674~679.
[2] Choi S-C, Xu Z, Li W, et al. Relative contributions of B cells and dendritic cells from Lupus-prone mice to CD4+ T cell polarization[J].Immunol 2018,135(supply 2):1~17.
[3] Ichiyama K, Gonzalez-Martin A, Kim B-S et al. The microRNA-183-96- 182 cluster promotes T helper 17 cell pathogenicity by negatively regulating transcription factor Foxo1 expression[J]. Immunity 2016, 44(6):1241~1243.
[4] Heink S, Yogev N, Garbers C,et al. Trans-presentation of IL-6 by dendritic cells is required for the priming of pathogenic TH17 cells[J].Nat Immunol, 2017,18(1):74~85.
[5] Sieper J, Porter-Brown B, Thompson L, et al. Assessment of short-term symptomatic efficacy of tocilizumab in ankylosing spondylitis: results of randomised, placebo-controlled trials[J].Ann Rheum Dis. 2014,73(1):95~100.
[6] Sieper J, Braun J, Kay J, et al. Sarilumab for the treatment of ankylosing spondylitis: results of a Phase II, randomised, double-blind, placebo-controlled study (ALIGN)[J].Ann Rheum Dis. 2015,74(6):1051~1057.
[7] Lee S.Y.Il-6 maybe a crucial role in peripheral arthritis of non-radiographic axial ankylosing spondylitis by toll-like receptor 2 and 4[J].Clinical and experimental rheumatology,2014,32(5):386.
[8] Duarte JH. Spondyloarthropathies: IL-17A blockade ameliorates ankylosing spondylitis[J].Nat Rev Rheumatol,2016,12(2):72.
[9] Wei, JCC ,Baeten, D ,Sieper, J , et al. Efficacy and safety of secukinumab in asian patients with active ankylosing spondylitis: 52-week pooled results from two phase 3 studies[J].International Journal of Rheumatic Dis-eases,2017,20(5):589~596.
[10] J. Braun, X. Baraliakos, A. Deodhar, D. et al. Effect of secukinumab on clinical and radio- graphic outcomes in ankylosing spondylitis: 2-year results from the randomised phase III MEASURE 1 study, Ann[J].Rheum. Dis,2017,76 (6) :1070~1077.
[11] A. Balato, E. Scala, N. Balato, G. et al. Ayala, biologics that inhibit the th17 pathway and related cytokines to treat inflammatory disorders, Expert Opin[J].Biol. Ther,2017,17 (11) :1363~1374.
[12] S.L. Gaffen, R. Jain, A.V. Garg, D.J. Cua, The IL-23-IL-17 immune axis: from mechanisms to therapeutic testing[J].Nature reviews, Immunology,2014,14 (9) :585~600.
[13] Lin TT,Lu J,Qi CY,et al. Elevated serum level of IL-27 and VEGF in patients with ankylosing spondylitis and associate with disease activity[J].Clinical and experimental medicine,2015,15(2):227~231.
[14] 李春龙,周洁,曹炬,等.IL-27诱导人成纤维样滑膜细胞产生IL-6的免疫机制[J].重庆医科大学学报,2018,43(6):824~828.
[15] Larousserie F,Bsiri L,Dumaine V,et al.Frontline science: human bone cells as a source of IL-27 under in-flammatory conditions: role of TLRs and cytokines[J].Journal Of Leukocyte Biology,2017,101,(6):1289~1300.
[16] E Kontny, K Bonek, P Gluszko. Associations of serum osteoprotegerin and IL-18 con-centrations with cardiovascular nrisk in ankylosing spondylitis and psoriatic arthritis patients[J].Annals of the Rheumatic Diseases,2017,76(Suppl 2):1310~1311.
[17] Sakellariou GT,Iliopoulos A,Konsta M,et al. Serum levels of Dkk-1, sclerostin and VEGF in patients with ankylosing spondylitis and their association with smoking, and clinical, inflammatory and radiographic parame-ters[J].Joint Bone Spine: Revue Du Rhumatisme,2017,84(3):309~315.